natgillin/translations-raw huggingface dataset:
Polymorphic Form A of N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide for use according to claim 11 in reducing the voluntary consumption of ethyl alcohol and/or in the treatment of the abstinences syndrome. 
Polimorfni oblik A N-[4-(trifluorometil)benzil]-4-metoksibutiramida, za primjenu u skladu sa zahtjevom 11 u smanjenju voljne konzumacije etil-lkohola i/ili u terapiji apstinencijalnog sindroma.
A viral particle released after infection of mammalian cells by human cytomegalovirus (HCMV), wherein the viral particle is a dense body, wherein 
Virusna čestica otpuštena nakon infekcija sisavačkih stanica ljudskim citomegalovirusom (HCMV), gdje virusna čestica je gusto tijelo, naznačena time što
the particle is surrounded by a lipid membrane in which viral glycoproteins are embedded, 
čestica je okružena lipidnom membranom, u koju su uklopljeni virusni glikoproteini;
the particle contains neither viral DNA nor capsids; and 
čestica ne sadrži ni virusnu DNA niti kapside; i
The viral particle according to any one of claims 1 to 2, wherein the amino acid sequence of the T-cell antigen pp65 comprises an amino acid sequence according to SEQ ID NO: 1. 
Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što aminokiselinski slijed T-staničnog antigena pp65 sadrži aminokiselinski slijed u skladu s SEQ ID NO: 1.
The viral particle according to claim 17, wherein the protein which is part of a human pathogen other than HCMV, is a protein against which cytotoxic T lymphocytes are formed in humans upon natural infection of humans with the human pathogen other than HCMV. 
Virusna čestica u skladu s patentnim zahtjevom 17, naznačena time što je protein koji je dio ljudskog patogena koji nije HCMV protein protiv kojeg se pojavljuju citotoksični T limfociti kod ljudi prilikom prirodne infekcije ljudi ljudskim patogenom koji nije HCMV.
The viral particle according to claim 18, wherein the human pathogen other than HCMV is human pathogen selected from the group comprising HIV-1, HBV, HCV and influenza. 
Virusna čestica u skladu s patentnim zahtjevom 18, naznačena time što ljudski patogen koji nije HCMV je ljudski patogen kojeg se bira iz skupine koju čine HIV-1, HBV, HCV i influenca.
The viral particle according to any one of claims 21 to 22, wherein the disease is a disease which can be treated and/or prevented by the formation of neutralizing antibodies against the at least one antigenic heterologous peptide or a derivative thereof, or by the induction of a CD8+ T lymphocyte response against the at least one antigenic heterologous peptide or a derivative thereof. 
Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 21 do 22, naznačena time što je bolest bolest koja se može liječiti i/ili spriječiti pojavom neutralizirajućih protutijela protiv najmanje jednog antigenog heterolognog peptida ili njegovog derivata, ili indukcijom CD8+ T limfocitnog odgovora protiv najmanje jednog antigenog heterolognog peptida ili njegovog derivata.
The viral particle according to claim 24, wherein the vaccine is for the treatment and/or prevention of HCMV infection. 
Virusna čestica u skladu s patentnim zahtjevom 24, naznačena time što je cjepivo namijenjeno liječenju i/ili sprječavanju infekcije HCMV-om.
The viral particle according to claim 24, wherein the vaccine is for the treatment and/or prevention of side effects of transplantation. 
Virusna čestica u skladu s patentnim zahtjevom 24, naznačena time što je cjepivo namijenjeno liječenju i/ili sprječavanju nuspojava presađivanja.
The viral particle according to claim 26, wherein the transplantation is transplantation of a solid organ or haematopoetic stem cells. 
Virusna čestica u skladu s patentnim zahtjevom 26, naznačena time što je presađivanje presađivanje čvrstog organa ili krvotvornih matičnih stanica.
a hydrophobic surfactant having an HLB value of below 8; 
hidrofobni tenzid koji ima HLB-vrijednost ispod 8;
a mucoadhesive galactomannan polymer; wherein: the oil phase is in droplets within the aqueous phase and the droplets have an average diameter that is no greater than about 1000 nm, but is at least 10 nm, wherein the average diameter is corresponding to 90% of the cumulative undersize distribution by volume measured using a Microtrac S3500 Particle Size Analyzer (Software Version 10.3.1); and 
uljna faza je u kapljicama unutar vodene faze i kapljice imaju prosječan promjer koji nije veći od oko 1000 nm, ali iznosi najmanje 10 nm, gdje prosječni promjer odgovara za 90% od kumulativne raspodjele čestica nedovoljne veličine po volumenu, koja se mjeri uporabom uređaja za analizu veličine čestica: „Microtrac S3500 Particle Size Analyzer“ (softverska verzija 10.3.1); i
An emulsion as in claim 1 or 2 wherein the oil is at least 0.1 w/v% and no greater than 5 w/v%, preferably at least 0.8 w/v% and no greater than 1.5 w/v% of the emulsion. 
Emulzija prema zahtjevu 1 ili 2, naznačena time, da ulje je u postotku od emulzije najmanje 0,1% masa/volumen i nije veći od 5% masa/volumen, poželjno je najmanje 0,8% masa/volumen, ali ne veći od 1,5% masa/volumen.
An emulsion as in claim 1, 2 and 3 wherein the hydrophilic surfactant is present in the emulsion in an amount that is at least 0.08 w/v% and is present in the emulsion in an amount that is no greater than 0.8 w/v%, preferably wherein the hydrophilic surfactant is present in the emulsion in an amount that is at least 0.14 w/v% and is present in the emulsion in an amount that is no greater than 0.44 w/v%. 
Emulzija prema zahtjevu 1, 2 i 3, naznačena time, da je hidrofilni tenzid prisutan u emulziji u količini koja je najmanje 0,08% masa/volumen i prisutan je u emulziji u količini koja nije veća od 0,8% masa/volumen, dok je poželjno hidrofilni tenzid prisutan u emulziji u količini koja je najmanje 0,14% masa/volumen i prisutan je u emulziji u količini koja nije veća od 0,44% masa/volumen.
An emulsion as in any of the preceding claims wherein the hydrophobic surfactant is present in the emulsion in an amount that is at least 0.11 w/v% and is present in the emulsion in an amount that is no greater than 2.0 w/v%, preferably wherein the hydrophobic surfactant is present in the emulsion in an amount that is at least 0.16 w/v% and is present in the emulsion in an amount that is no greater than 0.62 w/v%. 
Emulzija prema bilo kojem od prethodnih zahtjeva, naznačena time, da je hidrofobni tenzid prisutan u emulziji u količini koja je najmanje 0,11% masa/volumen i prisutan je u emulziji u količini koja nije veća od 2,0% masa/volumen, dok je poželjno hidrofobni tenzid prisutan u emulziji u količini koja je najmanje 0,16% masa/volumen i prisutan je u emulziji u količini koja nije veća od 0,62% masa/volumen.
An emulsion as in any of the preceding claims wherein the oil phase is in droplets within the aqueous phase and the droplets have an average diameter that is no greater than 500 nm but is at least 100 nm, wherein the average diameter is corresponding to 90% of the cumulative undersize distribution by volume measured using a Microtrac S3500 Particle Size Analyzer (Software Version 10.3.1). 
Emulzija prema bilo kojem od prethodnih zahtjeva, naznačena time, da je uljna faza u kapljicama unutar vodene faze i kapljice imaju prosječni promjer koji nije veći od 500 nm, ali je najmanje 100 nm, pri čemu prosječni promjer odgovara za 90% kumulativne distribucije čestica nedovoljne veličine po volumenu, koja se mjeri uporabom uređaja za analizu veličine čestica: „Microtrac S3500 Particle Size Analyzer“ (softverska verzija 10.3.1).
instilling the emulsion into an eye of a mammal. An emulsion as in claim 15 wherein the mammal is a human being and the emulsion is instilled as drops from an eye dropper. 
Emulzija prema zahtjevu 15, naznačena time, da sisavac je ljudsko biće i emulzija se daje u obliku kapljica koje se umeću pomoću kapaljke za oči.
A variant, recombinant human β-glucocerebrosidase protein having a mutation selected from: 
Varijanta, rekombinantnog ljudskog proteina β-glukocerebrozidaze, naznačena time da ima mutaciju odabranu od:
A and L317F; or H145L; and further comprising a mutation selected from K321N, K321A and K321V, wherein mutations are relative to the amino acid sequence of SEQ ID NO: 1. 
Varijanta, rekombinantnog ljudskog proteina β-glukocerebrozidaze prema zahtjevu 1, koja sadrži mutaciju F316A i L317F; ili H145L; te dodatno sadrži mutaciju odabranu od K321N, K321A i K321V, naznačena time da su mutacije u odnosu na sekvencu amino kiseline od SEQ ID NO: 1.
A variant, recombinant human β-glucocerebrosidase protein according to claim 1 or claim 2 having the amino acid sequence of SEQ ID NO: 2 or any one of SEQ ID NOs 4 to 16. 
Varijanta, rekombinantnog ljudskog proteina β-glukocerebrozidaze prema zahtjevu 1 ili zahtjevu 2, naznačena time da ima sekvencu amino kiseline od SEQ ID NO: 2 ili bilo koju od SEQ ID NO 4 do 16.
The variant, recombinant human β-glucocerebrosidase protein according to any one of claims 1 to 3 characterized as having an extended apparent half-life of at least 2-fold longer than wild-type, recombinant β-glucocerebrosidase. 
Varijanta, rekombinantnog ljudskog proteina β-glukocerebrozidaze prema bilo kojem od zahtjeva 1 do 3, naznačena time da ima produljeni poluvijek barem 2-struko dulji nego divlji tip, rekombinantne β-glukocerebrozidaze.
The variant, recombinant human β-glucocerebrosidase protein according to claim 7 wherein the extended apparent half-life is measured after incubation at conditions of neutral pH and 37°C over a period of three hours. 
Varijanta, rekombinantnog ljudskog proteina β-glukocerebrozidaze prema zahtjevu 7, naznačena time da se produljeni poluvijek mjeri nakon inkubacije u uvjetima neutralnog pH i 37°C tijekom perioda od tri sata.
The variant, recombinant human β-glucocerebrosidase protein according to claim 9 wherein the increased catalytic activity is measured after incubation at conditions of neutral pH and 37°C over a period of three hours. 
Varijanta, rekombinantnog ljudskog proteina β-glukocerebrozidaze prema zahtjevu 9, naznačena time da se povećana katalitička aktivnost mjeri nakon inkubacije u uvjetima neutralnog pH i 37°C tijekom perioda od tri sata.
A variant, recombinant human β-glucocerebrosidase protein for use according to claim 14, wherein the lysosomal storage disease is Gaucher disease. 
Varijanta, rekombinantnog ljudskog proteina β-glukocerebrozidaze, naznačena time da je za uporabu prema zahtjevu 14, naznačena time da lizosomska bolest nakupljanja je Gaucherova bolest.
A process for preparing a compound of formula 6a: wherein, 
Postupak za pripremu spoja formule 6a:
iib) cross coupling compound 2a and compound 3a in a biphasic mixture comprising water, a first organic solvent, a first base, and a transition metal catalyst to produce compound 4a, wherein, R1, o, and p are defined for compounds 2a and 3a above; 
iib) ukršteno uparivanje spoja 2a i spoja 3a u dvofaznoj smjesi koja sadrži vodu, prvo organsko otapalo, prvu bazu i katalizator od prijelaznog metala da se proizvede spoj 4a, [image] pri čemu su R1, o i p kako je gore definirano za spojeve 2a i 3a;
Sulphated hyaluronic acid for topical use for the hydratation treatment of skin pathologies characterized by dryness, lichenification, said sulphated hyaluronic acid (HA) having a molecular weight ranging from 150,000 to 250,000 Da and a sulphation degree equal to 1 or 3, intended as the number of sulfate groups per disaccharide unit, the sulfation involving the alcohol hydroxyls present in the polysaccharide chain. 
Sulfatirana hijaluronska kiselina za topikalnu primjenu za hidratacijsko djelovanje na patološka stanja kože naznačena time suhoće, lihenifikacije, a rečena sulfatirana hijaluronska kiselina (HA) ima molekulsku masu u rasponu od 150000 do 250000 Da, a stupanj sulfatiranja jest 1 ili 3, izražen kao broj sulfatnih skupina po disaharidnoj jedinici, a sulfatacijom su obuhvaćene alkoholne hidroksilne skupine prisutne u polisaharidnom lancu.
Sulphated hyaluronic acid for topical use for the prevention and/or treatment of skin pathologies associated with immune defence deficiency of IL-10 selected among vitiligo, eczema, psoriasis and dermatitis, stimulating the synthesis of anti-inflammatory cytokines, said sulphated hyaluronic acid (HA) having a molecular weight ranging from 150,000 to 250,000 Da or 500,000 to 750,000 Da and a sulphation degree equal to 1, intended as the number of sulfate groups per disaccharide unit, the sulfation involving the alcohol hydroxyls present in the polysaccharide chain. 
Sulfatirana hijaluronska kiselina za topikalnu primjenu za sprječavanje i/ili liječenje patoloških stanja kože povezanih s imunološkom obranom od deficijencije IL-10 odabranom od sljedećih: vitiligo, ekcem, psorijaza i dermatitis, a koja stimulira sintezu protuupalnih citokina, a rečena sulfatirana hijaluronska kiselina (HA) ima molekulsku masu u rasponu od 150000 do 250000 Da ili 500 000 do 750 000 Da, a stupanj sulfatiranja jest 1, izražen kao broj sulfatnih skupina po disaharidnoj jedinici, a sulfatacijom su obuhvaćene alkoholne hidroksilne skupine prisutne u polisaharidnom lancu.
The pharmaceutical composition for use according to the previous claims 3 or 4, containing steroids, hormones, proteins, trophic factors, vitamins, non-steroid anti-inflammatory drugs, chemotherapy drugs for topical use, antibiotics, antiviral agents, local anesthetics, anticoagulants and/or fibrinolytic agents, enzymes and/or other proteases. 
Farmaceutski pripravak za upotrebu prema prethodnim patentnim zahtjevima 3 ili 4, koji sadržava steroide, hormone, proteine, tropičke faktore, vitamine, nesteroidne protuupalne lijekove, lijekove za kemoterapiju za topikalnu primjenu, antibiotike, antivirusna sredstva, lokalne anestetike, antikoagulanse i/ili fibrinolitička sredstva, enzime i/ili druge proteaze.
The pharmaceutical composition for use according to claims 3-5, containing polymers such as hyaluronic acid and its derivatives, carboxymethylcellulose and/or other polymers of a natural or synthetic origin. 
Farmaceutski pripravak za upotrebu prema patentnim zahtjevima 3 - 5, koji sadržava polimere kao što je hijaluronska kiselina i njeni derivati, karboksimetilceluloza i/ili drugi polimeri prirodnog ili sintetičkog porijekla.
The pharmaceutical composition for use according to claims 3-6, in the form of an ointment, lipogel, hydrogel, lipstick, cream, patches, vaginal ovules and bougies, foam, mucosal gel, ophthalmic preparations, vaginal douches, mouthwash, solutions for topical application or inhalation. 
Farmaceutski pripravak za upotrebu prema patentnim zahtjevima 3 - 6, koji je u obliku masti, lipogela, hidrogela, ruža, kreme, flastera, vaginalnih ovula i čepića, pjene, gela za sluznicu, oftalmoloških pripravaka, vaginalnih tekućina, tekućine za ispiranje usta, otopina za topikalnu primjenu ili inhalaciju.
The shipping container (1) of claim 3 wherein said cradle portion (100) is formed of a first material and said basket (20) is formed of a different material. 
Transportna kutija (1) iz zahtjeva 3, pri čemu je navedena temeljna podloga (100) izrađena od jednog materijala, a navedena košara (20) od drugog materijala.
The shipping container (1) of claim 3 wherein the cradle portion (100) is formed of wood and the basket portion (20) is formed of a polymeric material. 
Transportna kutija (1) iz zahtjeva 3, pri čemu je temeljna podloga (100) izrađena od drveta, a košara (20) od polimera.
A compound of any one of claims 1 to 29 or a pharmaceutically acceptable salt thereof for use in treating atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity, endotoxemia or metabolic syndrome; or preventing or delaying the progression of Alzheimer's disease or other neurodegenerative diseases. 
Uporaba spoja prema bilo kojem od Zahtjeva 1 do 29, ili neke njegove farmaceutski prihvatljive soli u tretiranju ateroskleroze, periferne vaskularne bolesti, dislipidemije, hiperbetalipoproteinemije, hipoalfalipoproteinemije, hiper-kolesterolemije, hipertrigliceridemije, obiteljske-hiperkolesterolemije, kardio-vaskularnih poremećaja, angine, ishemije, srčane ishemije, moždanog udara, infarkta miokarda, reperfuzijske ozljede, angioplastne restenoze, hipertenzije, vaskularne komplikacije od dijabetesa, pretjerane debljine, endotoksemije ili metaboličkog sindroma; ili u prevenciji ili odgađanju napredovanja Alzheimer-ove bolesti ili drugih neurodegenerativnih bolesti.
A combination comprising a compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof and other drugs for use in treating atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity, endotoxemia or metabolic syndrome; preventing or delaying the progression of Alzheimer's disease or other neurodegenerative diseases; or raising HDL-C or lowering LDL-C. 
Uporaba kombinacije koja sadrži Spoj prema bilo kojem od Zahtjeva 1 to 29, ili neku njegovu farmaceutski prihvatljivu sol i druge lijekove u tretiranju ateroskleroze, periferne vaskularne bolesti, dislipidemije, hiperbetalipoproteinemije, hipoalfalipoproteinemije, hiperkolesterolemije, hipertrigliceridemije, obiteljske-hiperkolesterolemije, kardiovaskularnih poremećaja, angine, ishemije, srčane ishemije, moždanog udara, infarkta miokarda, reperfuzijske ozljede, angioplastne restenoze, hipertenzije, vaskularne komplikacije od dijabetesa, pretjerane debljine, endotoksemije ili metaboličkog sindroma; prevencije ili odgađanja napredovanja Alzheimer-ove bolesti ili drugih neurodegenerativnih boleti; ili podizanju HDL-C ili snižavanju LDL-C.
A host cell comprising the nucleic acid according to claim 5 or the expression vector according to claim 6, wherein said host cell is not a human embryonic stem-cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline u skladu s patentnim zahtjevom 5 ili vektor ekspresije u skladu s patentnim zahtjevom 6, pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T- limfocita (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim od patentnih zahtjeva 1 ili 2.
The peptide according to any one of claims 1 to 4 for use in the treatment of cancer or for use in the manufacture of a vaccine against cancer. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4 za uporabu u liječenju karcinoma ili za uporabu u proizvodnji cjepiva protiv karcinoma.
The peptide according to any one of claims 1 to 4 for use according to claim 13 or 14, wherein said vaccine furthermore comprises at least one additional peptide selected from SEQ ID No 1 to SEQ ID No 9, and SEQ ID No 11 to SEQ ID No 26. 
Peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 4 za uporabu u skladu s patentnim zahtjevom 13 ili 14, pri čemu se navedeno cjepivo nadalje sastoji od najmanje jednog dodatnog peptida odabranog iz SEQ ID br. 1 do SEQ ID br. 9, i SEQ ID br. 11 do SEQ ID br. 26.
A kit comprising a container containing a pharmaceutical composition containing the peptide according to any one of claims 1 to 4 or the activated cytotoxic T lymphocyte according to claim 11, in solution or in lyophilized form. 
Komplet koji sadrži posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11, u otopini ili u liofiliziranom obliku.
A method of producing a feed additive composition for ruminants, comprising the steps of: preparing a molten mixture formed from at least one protective agent selected from a hydrogenated vegetable oil and a hydrogenated animal oil having a melting point higher than 50°C and lower than 90°C, lecithin in an amount to achieve a content of lecithin in the feed additive composition of 1 to 2 % by weight, and an acidic or neutral amino acid; and 
pripremanje rastaljene smjese načinjene od najmanje jednog zaštitnog sredstva odabranog iz skupine koju čine hidrogenirana biljna ulja i hidrogenirana životinjska ulja s točkom taljenja višom od 50°C i nižom od 90°C, lecitin u količini potrebnoj da se postigne težinski udjel lecitina u pripravku za dodatak hrani od 1 do 2 % i kisela ili neutralna aminokiselina; i dobivanje očvrsnute smjese uranjanjem spomenute rastaljene smjese u vodu.
obtaining a solidified mixture by immersing said molten mixture into water. The method of producing a feed additive composition for ruminants according to claim 1, wherein said step of preparing a molten mixture comprises preparing a molten mixture through heating and melting using an extruder, and said step of obtaining a solidified mixture comprises obtaining a solidified mixture by allowing the molten mixture which is retained in a multi-hole shooter having a plurality of holes at the vessel bottom to fall through said plurality of holes to be immersed into water. 
Postupak za proizvodnju pripravka za dodatak hrani za preživače u skladu s patentnim zahtjevom 1, naznačen time, da korak priprave rastaljene smjese podrazumijeva pripremu rastaljene smjese grijanjem i taljenjem pomoću ekstrudera, a navedeni korak dobivanja očvrsnute smjesa podrazumijeva dobivanje očvrsnute smjese tako što se rastaljena smjesa koja se nalazi u injektoru s većim brojem otvora na dnu posude propusti kroz veći broj otvora i uroni u vodu.
The method of producing a feed additive composition for ruminants according to claim 1 or 2, further comprising a step of heat-treating the solidified mixture. 
Postupak za proizvodnju pripravka za dodatak hrani za preživače u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da dodatno podrazumijeva korak termičke obrade očvrsnute smjese.
3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of acute exacerbations of chronic obstructive pulmonary disease. 
-[5-amino-4-(3-cijanobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid ili njegova farmaceutski prikladna sol, hidrat ili solvat za uporabu u liječenju akutnih pogoršanja (egzacerbacija) kronične opstruktivne plućne bolesti.
An oral pharmaceutical composition that contains 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of acute exacerbations of chronic obstructive pulmonary disease. 
Oralni farmaceutski pripravak koji sadrži 3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid ili njegovu farmaceutski prikladnu sol, hidrat ili solvat za uporabu u liječenju akutnih pogoršanja (egzacerbacija) kronične opstruktivne plućne bolesti.